skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Review

(1866) Views  (767) Full article downloads

Authors: Giuseppe Camporese, Enrico Bernardi, Franco Noventa

Published Date September 2009 Volume 2009:5 Pages 819 - 831
DOI: http://dx.doi.org/10.2147/VHRM.S3430

Giuseppe Camporese1, Enrico Bernardi2, Franco Noventa3

1Unit of Angiology and 3Department of Clinical and Experimental Medicine, Clinical Epidemiology Group, University Hospital of Padua, Italy; 2Department of Emergency and Accident Medicine, Hospital of Conegliano Veneto, Italy

Abstract: Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.

Keywords: low-molecular-weight heparin, heparin, parnaparin, acute coronary syndromes, venous thromboembolism








Readers of this article also read:

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants
Comparative assessment of angiotensin receptor blockers in different clinical settings
Early cardiovascular abnormalities in newly diagnosed obstructive sleep apnea
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University